Navigation Links
Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
Date:5/10/2011

ng aplastic anemia, have been reported with TNF blockers.  Medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) has been infrequently reported with certolizumab pegol.  Advise all patients to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on certolizumab pegol.  Consider discontinuation of certolizumab pegol therapy in patients with confirmed significant hematologic abnormalities.

Drug Interactions

An increased risk of serious infections has been seen in clinical trials of other TNF blocking agents used in combination with anakinra or abatacept.  Formal drug interaction studies have not been performed with rituximab or natalizumab; however because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also result from the use of certolizumab pegol in these combinations.  Therefore, the combination of certolizumab pegol with anakinra, abatacept, rituximab, or natalizumab is not recommended.  Interference with certain coagulation assays has been detected in patients treated with certolizumab pegol.  There is no evidence that certolizumab pegol therapy has an effect on in vivo coagulation.  Certolizumab pegol may cause erroneously elevated aPTT assay results in patients without coagulation abnormalities.

Autoimmunity

Treatment with certolizumab pegol may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome.  Discontinue treatment if symptoms of lupus-like syndrome develop.

Immunizations

Do not administer live vaccines or attenuated vaccines concurrently with certolizumab pegol.

Adverse Reactions

In controlled Crohn's cl
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
2. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
3. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
4. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
5. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
6. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
7. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
8. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
9. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
10. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
11. New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
(Date:12/19/2014)... separating membrane market has witnessed robust development with ... albeit as a later starter. In 2012, the size of ... RMB12 billion, with the proportion worldwide soaring to 16.3%. It ... market will continue its growth rate by around 20% in ... jump to roughly RMB25 billion. An integrated membrane ...
(Date:12/17/2014)... December 17, 2014 Los beneficios ... un alto nivel de gasto en investigación y desarrollo ... (finalizado el 30 de septiembre de 2014) ZEISS aumentó ... millones de euros (año anterior: 4.190 millones de euros) ... Las ganancias (EBIT) crecieron un 14 por ciento, a ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3ZEISS confirma su posición en un entorno difícil 2
... ALTO, Calif., Oct. 1 Telik, Inc. (Nasdaq: TELK ... a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination ... nonsmall cell lung cancer (NSCLC) in a leading peer reviewed ... Vol. 4, No. 10. Data on this study were ...
... , MOUNTAIN VIEW, Calif., Oct. 1 IRIDEX Corporation ... FlexFiber(TM) a laser fiber probe intended for effective delivery ... procedures. Introduced at the 2009 American Academy of ... , this consumable product represents an increase in IRIDEX, ...
Cached Medicine Technology:Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer 2IRIDEX Introduces New ENT Laser Delivery Devices at AAO-HNSF Annual Meeting 2
(Date:12/20/2014)... The holidays can be anything but joyous for people ... candles and other allergy triggers. "The dust from ... packed away in dank basements or dusty attics is ... Rachna Shah, an affiliate faculty member at Loyola University ... release. Shah, who is also an allergist at ...
(Date:12/20/2014)... 20, 2014 The Doctor’s Office Urgent Care ... better part of a decade. They’ve treated over 40,000 ... faster healthcare alternative to the Paramus area. ... new additions to their staff of top-notch board certified physicians: ... MD. These new doctors will work tirelessly to ...
(Date:12/20/2014)... New York (PRWEB) December 20, 2014 ... continue to move forward in U.S. courts, Bernstein ... study which suggests that children treated with the ... hormone linked to breast development and lactation. The ... at 34 children and adolescents who began treatment ...
(Date:12/20/2014)... 20, 2014 The aftermath of the November ... stir, not only in Hollywood, but worldwide. As ... the ripples of that attack are starting a finger-pointing game ... risk. But they are not the only ones affected, ... in for some embarrassing times ahead, agents and lawyers could ...
(Date:12/20/2014)... 2014 Developers of FCPX ... new plugin for Final Cut Pro X entitled TranSlice ... 5 allows users to create hand drawn text animations ... Austin, CEO of Pixel Film Studios. “TranSlice Volume 5 ... maintaining an easy to use interface.” , TranSlice Volume ...
Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... , , , NEW YORK, ... is available in its catalogue. , , ... http://www.reportlinker.com/p0131247/Lung-Cancer-Therapeutics.html , , ... Cancer Therapeutics in Millions of US$. The US market for Non-Small ...
... ... Diego, CA adds General Motors and Qualcomm to the program! , ... Portland, ME (PRWEB) September 8, 2009 -- Image Sensors ... San Diego, CA. The 3rd annual international event will address the latest trends and technologies ...
... , , , Will ... , , NEW YORK, Sept. 8 MARK ... of Lighthouse International, the 104-year-old non-profit leader in vision healthcare, research, ... in healthcare management, will start in his new role on September ...
... , ... head back to school , ... (PRWEB) September 8, 2009 -- As the unemployment rate in Canada holds steady at 8.6%, more ... the recession. , , , ,CDI College, a career college with 13 campus locations across Canada, ...
... The New York Football Giants are asking their fans to ... EAST RUTHERFORD, N.J., Sept. 8 We heard you bleed BLUE! ... ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20090908/DC71650LOGO ) , , On ... with the American Red Cross to host a blood drive. The ...
... Sept. 8 Give an Hour(TM), a national nonprofit organization providing ... their loved ones, announces results of its August 2009 survey and ... survey in May 2009. , , Give an ... effectiveness and to determine how programs and services can be adapted ...
Cached Medicine News:Health News:Reportlinker Adds Lung Cancer Therapeutics Report 2Health News:Reportlinker Adds Lung Cancer Therapeutics Report 3Health News:Reportlinker Adds Lung Cancer Therapeutics Report 4Health News:Reportlinker Adds Lung Cancer Therapeutics Report 5Health News:Reportlinker Adds Lung Cancer Therapeutics Report 6Health News:Reportlinker Adds Lung Cancer Therapeutics Report 7Health News:Reportlinker Adds Lung Cancer Therapeutics Report 8Health News:Reportlinker Adds Lung Cancer Therapeutics Report 9Health News:Reportlinker Adds Lung Cancer Therapeutics Report 10Health News:Image Sensors 2009 Offers Promotional Discount on Machine Vision and Wireless Power Summits 2Health News:Image Sensors 2009 Offers Promotional Discount on Machine Vision and Wireless Power Summits 3Health News:Mark G. Ackermann Is Named New President and CEO of Lighthouse International 2Health News:Mark G. Ackermann Is Named New President and CEO of Lighthouse International 3Health News:Fall 2009 Sees Spike in Enrollments at CDI College 2Health News:New York Giants to Host American Red Cross Blood Drive 2Health News:Give an Hour(TM)'s Volunteer Mental Health Professionals Provide Nearly $1.7 Million in Services to Iraq and Afghanistan Veterans, Families, and Communities 2
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: